Alan Shearer has voiced his support for Alan Pardew after Newcastle confirmed the manager will continue next season.
The former Newcastle striker was speaking at a charity golf day in Northumberland in aid of the Children's Heart Unit and the Freeman Hospital.
He told ITV Tyne Tees: "You can't sell your best player and not replace him and I think that's why everyone was so unhappy."
Ant and Dec were still celebrating their BAFTAs success as they took part in a charity golf day in Newcastle.
Despite little sleep, the Geordie duo were on form on the fairways, raising money for the Children's Heart Unit at the Freeman hospital in Newcastle.
Ten week old Chanel Murrish is called a little miracle by her mum. The baby, from County Durham, is recovering well after undergoing open heart surgery - just minutes after being born. An extremely rare heart condition has seen her undergo SEVEN procedures already. Jonny Blair reports.
The mum of Chanel Murrish, who had open heart surgery at The Freeman Hospital just minutes after being born, describes her baby's personality:
Ten week old Chanel Murrish, from County Durham, had open heart surgery just minutes after being born at The Freeman Hospital in Newcastle. She's still being treated there and her mum has praised the staff.
Fay Murrish's daughter Chanel is just ten weeks old but already has had seven medical procedures because of a rare heart condition. She had open heart surgery just minutes after being born.
A new life-extending breast cancer drug trialled in the North East, is deemed too expensive for the NHS.Read the full story ›
Kadcyla, a drug that can offer some women with advanced breast cancer nearly six months of extra life, which was trialled here in the North East, has for now been rejected for use in the NHS, because of its high cost.
A Newcastle doctor whose patients have been involved in the clinical trials is disappointed by the decision.
Dr Mark Verrill, from the Freeman Hospital, say the drug is revolutionary.
A new drug for breast cancer which extends women's lives by almost six months could be blocked from routine NHS access under draft guidance issued by a health watchdog.
Kadcyla, manufactured by Roche, can cost more than £60,000 per patient and is not effective enough to justify the price, the National Institute for Health and Clinical Excellence, NICE, said.
Patients will be able to apply to their local NHS and to the Cancer Drugs Fund (CDF) for the drug, a Nice spokeswoman said.
But the decision, if made final later this year, would mean the drug would not be recommended for routine use in England on the NHS and women would have to rely on their doctors' successful application to the Cancer Drugs Fund.
Sir Andrew Dillon, Nice chief executive, said he hoped Roche would "act in the best interest of patients" .
He said: "We apply as much flexibility as we can in approving new treatments, but the reality is that given its price and what it offers to patients, it will displace more health benefit which the NHS could achieve in other ways, than it will offer to patients with breast cancer."
Jayson Dallas, general manager, Roche Products Limited, said: "Roche is extremely disappointed that Nice has failed to safeguard the interests of patients with this advanced stage of aggressive disease."